The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment By Annika Kim Constantino,CNBC • Published January 21, 2025 • Updated on January 21, 2025 at 11:04 am BOOKMARKER ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug ...

In just over five minutes, Johnson & Johnson tackles the complicated nature of living with depression — both from the perspective of patients and caregivers — in a recently released short film.

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...

On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment ...

Johnson & Johnson JNJ 0.16 % increase; green up pointing triangle agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about $15 billion, evidence of the pharmaceutical ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug ...

On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The ...